A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania

References

• Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11:999–1029.
   PubMedGoogle Scholar
• McIntyre RS. Long-term treatment of bipolar disorder in adults. J Clin Psychiatry 2011;72:e06.
   Google Scholar
• Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007;7:40.
   PubMed Web of Science ®Google Scholar
• Goodwin GM; Consensus Group of the British Association for Psychopharmacology.Evidence-based guidelines for treating bipolar disorder: revised second edition— recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346–88.
   PubMed Web of Science ®Google Scholar
• Ertugrul A, Meltzer HY. Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003;6:277–84.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. NICE Clinical Guideline 38: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. July 2006. Available at http://www.nice.org.uk/nicemedia/live/10990/30193/30193.pdf. Accessed 12 December 2011.
   Google Scholar
• Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11: 225–55.
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, . The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85–116.
   PubMed Web of Science ®Google Scholar
• SPC. Aripiprazole Summary of Product Characteristics. Bristol-Myers Squibb and Otsuka Pharmaceutical Europe Ltd, 2009. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000471/WC500020170.pdf. Accessed 12 December 2011.
   Google Scholar
• Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008;69(Suppl 4):26–36.
   PubMedGoogle Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA, . The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137–40.
   PubMed Web of Science ®Google Scholar
• Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract 2003;57:49–54.
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA, . In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45–53.
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, . Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381–9.
   PubMed Web of Science ®Google Scholar
• Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 2008;597:27–33.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, ‘Goldilocks’ actions at dopamine receptors. J Clin Psychiatry 2001;62:841–2.
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002;1:141–7.
   PubMedGoogle Scholar
• Fagiolini A, Nitti M, Forgione RN, Marra FS, Casamassima F. Aripiprazole for the treatment of bipolar disorder: a review of current evidence. Expert Opin Pharmacother 2011;12: 473–88.
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, . Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400–11.
   PubMed Web of Science ®Google Scholar
• Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, . A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88:63–72.
   PubMed Web of Science ®Google Scholar
• Masand PS, Culpepper L, Henderson D, Lee S, Littrell K, Newcomer JW, . Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr 2005;10(Suppl 14):1–15.
   Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21:911–36.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008;69(Suppl 1):32–44.
   PubMedGoogle Scholar
• Hanssens L, L’Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W, . The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008;8:95.
   PubMed Web of Science ®Google Scholar
• Montejo AL, Riesgo Y, Luque J, Barber I ; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole. Actas Esp Psiquiatr 2010;38:13–21.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr. Antipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry 2000;61(Suppl 8):52–61
   PubMedGoogle Scholar
• Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG, . The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009;166:1055–62.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 2003;74:277–90.
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, ; Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480–91.
   PubMed Web of Science ®Google Scholar
• De Fazio P, Girardi P, Maina G, Mauri MC, Mauri M, Monteleone P, . Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group. Clin Drug Investig 2010;30:827–41.
   PubMed Web of Science ®Google Scholar
• Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, . Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011;13:133–44.
   PubMed Web of Science ®Google Scholar
• Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1213–9.
   PubMed Web of Science ®Google Scholar
• Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry 2008;69(Suppl 1):18–31.
   PubMedGoogle Scholar
• IM SPC. Aripiprazole 7.5 mg/mL solution for injection (intramuscular) Summary of Product Characteristics. Bristol-Myers Squibb and Otsuka Pharmaceutical Europe Ltd, 2011. Available at http://www.medicines.org.uk/EMC/medicine/20802/SPC/Abilify+7.5+mg+ml+solution+for+injection+(intramuscular)+(Bristol-Myers+Squibb+ Pharmaceuticals+Ltd)/ . Accessed 12 December 2011.
   Google Scholar
• Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, ; Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651–8.
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, ; Aripiprazole Study Group. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20:536–46.
   PubMed Web of Science ®Google Scholar
• Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, ; CN138-135 Study Group. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009;112:36–49.
   PubMed Web of Science ®Google Scholar
• El Mallakh RS, Vieta E, Rollin L, Marcus R, Carson WH, McQuade R. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). Eur Neuropsychopharmacol 2010;20: 776–83
   PubMed Web of Science ®Google Scholar
• Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, . Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009;194:40–8.
   PubMed Web of Science ®Google Scholar
• Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, ; Aripiprazole Study Group. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235–42.
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, ; < Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626–37.
   PubMed Web of Science ®Google Scholar
• Vieta E, T'joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R, . Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008;165: 1316–25.
   PubMed Web of Science ®Google Scholar
• Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN, . Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010;26:1485–96.
   PubMed Web of Science ®Google Scholar
• Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, . Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27:171–6.
   PubMed Web of Science ®Google Scholar
• El Mallakh RS, Marcus RN, Baudelet C, McQuade RD, Carson WH, Owen R, . A 52-week, double-blind safety and efficacy evaluation of aripiprazole monotherapy versus lithium in bipolar disorder (CN138-135LT). Poster (P63) presented at the 8th International Conference on Bipolar Disorder, June 25–27 2009, Pittsburgh, PA, USA.
   Google Scholar
• Rana TA, Malik T. Clinical trials to clinical practice: retrospective analysis of 25 patients with bipolar mania treated with aripiprazole. Prog Neurol Psychiatry Case Notes 2010;14(5 Suppl):1–8.
   Google Scholar
• Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009;8:16.
   PubMedGoogle Scholar
• Muzina DJ. Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole. Neuropsychiatr Dis Treat 2009;5:279 − 88.
   PubMed Web of Science ®Google Scholar
• Liemburg E, Aleman A, Bous J, Hollander K, Knegtering H. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry 2011;44:109–13.
   PubMedGoogle Scholar
• Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol 2011;25:646–66.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Abbar M, Schlaepfer TE, Grunze H, Licht RW, Bellivier F, . Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance. Curr Med Res Opin 2011;27:2285–99.
   PubMed Web of Science ®Google Scholar
• Parker C, Khwaja MG. What is new in rapid tranquillisation?J Psychiatr Intens Care 2011;7:91–101.
   Google Scholar
• National Institute for Health and Clinical Excellence. NICE Clinical Guideline 25: Violence: The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. February 2005. Available at http://publications.nice.org.uk/violence-cg25. Accessed 30 April 2012.
   Google Scholar
• Day RK. Psychomotor agitation: poorly defined and badly measured. J Affect Disord 1999;55:89–98.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia, 2nd edition, 2004. Available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_6.aspx. Accessed 12 December 2011.
   Google Scholar
• Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull 2003;29:547–58.
   PubMed Web of Science ®Google Scholar
• Sullivan G, Bienroth M, Jones M, Millar H, Ratna L, Taylor D, . Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 2007;23: 1733–44.
   PubMed Web of Science ®Google Scholar